Connection and Care at Every Step Mental health doesn’t exist in a vacuum—it’s shaped by relationships, community, and support systems. Active Path recognizes the power of connection and offers ...

Mental health providers in Central Illinois offering ketamine say it has changed patients' lives for the better. Still, only ...

Regulatory delays could hinder Mind Medicine's patient access and market entry. Read why we are initiating coverage on MNMD ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on JNJ: Disclaimer & Disclosure Report an Issue Johnson & Johnson NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

AptarGroup is poised for growth in its Pharma and Closure segments, but challenges are expected in the Beauty segment. See ...

On the positive side, continued growth in sales of key drugs like Darzalex, along with newer products such as Erleada and ...

As we honor Counseling Awareness Month,�Relief Mental Health recognizes the critical role that therapy plays in helping individuals navigate mental health challenges and build a life worth living.

In 2019, the Food and Drug Administration approved esketamine (Spravato), a nasal spray for treatment-resistant depression. Research indicates that ketamine therapy helps individuals who did not ...

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.